Trade Ligand Pharmaceuticals Incorpor - LGND CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.72 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023485% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001262% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 104.79 |
| Open | 103.4 |
| 1-Year Change | 41.76% |
| Day's Range | 102.2 - 106.97 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | 104.79 | -0.11 | -0.10% | 104.90 | 104.99 | 101.57 |
| Mar 28, 2025 | 107.32 | -0.25 | -0.23% | 107.57 | 109.58 | 106.06 |
| Mar 27, 2025 | 109.09 | 3.15 | 2.97% | 105.94 | 112.11 | 104.89 |
| Mar 26, 2025 | 107.71 | -0.47 | -0.43% | 108.18 | 110.89 | 106.85 |
| Mar 25, 2025 | 109.30 | -0.12 | -0.11% | 109.42 | 112.20 | 108.91 |
| Mar 24, 2025 | 110.93 | 4.13 | 3.87% | 106.80 | 112.58 | 106.80 |
| Mar 21, 2025 | 107.99 | 0.62 | 0.58% | 107.37 | 111.14 | 106.12 |
| Mar 20, 2025 | 109.36 | 2.68 | 2.51% | 106.68 | 110.51 | 106.68 |
| Mar 19, 2025 | 107.86 | 2.36 | 2.24% | 105.50 | 108.13 | 104.57 |
| Mar 18, 2025 | 105.97 | -0.09 | -0.08% | 106.06 | 107.03 | 102.51 |
| Mar 17, 2025 | 109.71 | 5.61 | 5.39% | 104.10 | 112.37 | 102.83 |
| Mar 14, 2025 | 106.14 | 2.88 | 2.79% | 103.26 | 108.46 | 103.26 |
| Mar 13, 2025 | 105.20 | -1.18 | -1.11% | 106.38 | 107.89 | 103.04 |
| Mar 12, 2025 | 107.14 | 2.84 | 2.72% | 104.30 | 110.35 | 104.30 |
| Mar 11, 2025 | 105.39 | -3.04 | -2.80% | 108.43 | 108.43 | 104.50 |
| Mar 10, 2025 | 109.12 | -3.46 | -3.07% | 112.58 | 112.58 | 105.70 |
| Mar 7, 2025 | 114.76 | 2.60 | 2.32% | 112.16 | 116.79 | 110.53 |
| Mar 6, 2025 | 115.58 | 4.37 | 3.93% | 111.21 | 116.14 | 109.48 |
| Mar 5, 2025 | 114.67 | -0.63 | -0.55% | 115.30 | 115.92 | 110.19 |
| Mar 4, 2025 | 117.27 | 6.32 | 5.70% | 110.95 | 117.31 | 107.88 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Ligand Pharmaceuticals Incorpor Company profile
About Ligand Pharmaceuticals Inc.
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company. The Company is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development or research and are fully funded by its collaboration partners and licensees. Its technologies include OmniAb Technologies, Pelican Expression Technology Platform, Captisol Technology, HepDirect, LTP, BEPro Technology Platform, and SUREtechnology Platform. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies. The Pelican Expression Technology is a scalable platform for recombinant protein production and is suited for complex, large-scale protein production. Captisol is a chemically modified cyclodextrin designed to optimize the stability of drugs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Ligand Pharmaceuticals Inc. revenues increased 49% to $277.1M. Net income totaled $57.1M vs. loss of $3M. Revenues reflect Captisol segment increase of 49% to $164.3M, Milestone segment increase from $11.5M to $28.7M. Net Income reflects Gain (loss) from short-term investments decrease of 76% to $4M (expense), Other General and administrative decrease of 23% to $36.1M (expense).
Equity composition
Common Stock $.006 Par, 3/11, 33,333,3333 auth., 20,644,234 issd., less 1,118,222 shs in Treas. @ $42.3M. Insiders own 3.36%. IPO:11/92, 4.3M Class A shares @ $11 by Lehman Bros. FY'00 Q's are restated for SAB 101 adjustment. 9/05,Co. delisted from NASDAQ to OTC.11/10, 1-for-06 Reverse Stock split.
| Industry: | Pharmaceuticals (NEC) |
3911 Sorrento Valley Blvd
Suite 110
SAN DIEGO
CALIFORNIA 92121
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com